AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02283411 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Abbott Sensor Based Glucose Monitoring System
Description: Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
Study NCT00712634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMVpp65-A*0201 peptide vaccine
Description: Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
Study NCT03651375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy - 3 courses of AI
Description: Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between radiotherapy and surgery.
Study NCT01436474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
Study NCT03651375 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with a daily image guidance with cone beam-CT-based position verification.
Study NCT04766528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 maximal aerobic tests
Description: Maximal aerobic tests will be performed before diet intervention, after the first diet and after the second diet
Study NCT02411032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Customer gets mailing that reminds them to take their medication.
Study NCT02893696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Various sitting time
Description: Various sitting time
Study NCT02411032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fresh start
Description: Customers receive a mailing around a fresh start event: New Year's or birthday
Study NCT01472068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inko RS Device
Description: 30 minute pre-programmed treatment for 5 days out of 7. Treatment to be carried out while standing.
Study NCT04526041 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nasofibroscopy
Description: Laryngeal exploration performed using a flexible fibrescope while singing.
Study NCT02411032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fresh start framing
Description: The fresh start event will be highlighted in the mailings.
Study NCT04526041 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electroglottography
Description: Electrography of glottal movement using the EG2-PCX2 system (Glottal enterprises) while singing.
Study NCT04526041 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Air flow measurement + acoustic signal recording
Description: Air flow measurement and acoustic signal recording while singing using the EVA2 system (SQLab-LPL, Aix en Provence, France)
Study NCT04526041 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Questionnaire on subject singing habits, the way it use and perceive the use of his body when singing.
Study NCT00119782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environment
Description: Increase worksite access to both healthy foods and physical activity
Study NCT03043287 — intervention group
Intervention type: BIOLOGICAL
Intervention: onabotulinumtoxinA
Description: onabotulinumtoxinA (BOTOX®)100 to 200 U
Study NCT02257970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Study NCT02257970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen
Study NCT02257970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ketoprofen.
Study NCT02926833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTE-C19
Description: A single infusion of KTE-C19 CAR-T cells administered intravenously
Study NCT02926833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered intravenously
Study NCT02926833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously
Study NCT02926833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study NCT04423692 — intervention group
Intervention type: OTHER
Intervention: labs
Description: A group of questions to women regarding Corona with laboratory finding suggestive of covid 19 and coagulopathy
Study NCT04099784 — intervention group
Intervention type: OTHER
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
Study NCT02801487 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy (CIRT)
Description: Five dose levels (52.5GyE, 55GyE, 57.5GyE, 60GyE, 62.5GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 62.5 GyE are safely delivered, the recommended dose (or 62.5 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the GTV+3\~5mm.
Study NCT02801487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (40mg/m\^2) monotherapy will be given weekly along with radiotherapy.
Study NCT04533932 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Elastography
Description: Endosonographic shear wave elastography
Study NCT02581657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PE0139 Injection
Description: PE0139 Injection
Study NCT02581657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Placebo Injection
Study NCT03961984 — intervention group
Intervention type: PROCEDURE
Intervention: Biodesign® anal fistula plug
Description: Patient in general anesthesia and lithotomy position. Mucosa excision of the internal fistula opening is performed. The plug was prepared in 0.9% sodium chloride, and secured to the endoluminal brush by a suture with a 2-0 vicryl tie. The narrow end of the of the plug was then pulled through the internal opening into the fistula tract. The plug was pulled until it covered the whole length of the fistula and blocked the internal opening, the excess plug material coming out through the external opening. The plug was fixed at the internal opening by reabsorbable 3-0 sutures. Special attention was paid to ensuring that the plug was covered by mucosa when closing the internal opening. The excess plug material was trimmed by the external opening that was left open for drainage.
Study NCT03391063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polyamide
Description: metal reinforced polyamide denture base material
Study NCT03391063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: heat cured acrylic resin
Description: conventional heat cured acrylic resin denture base material
Study NCT01977664 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT01973673 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone health educational materials
Study NCT00496782 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: maraviroc
Description: Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
Study NCT00496782 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Trofile Assay and HIV RNA quantification assay
Description: Trofile Assay and HIV RNA quantification assay
Study NCT03303352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS FNA
Description: Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will be randomly allocated to receive EUS FNA (endoscopic ultrasound fine needle aspiration).
Study NCT02221882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3164530
Description: Administered IV.
Study NCT01870765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive ventilation
Description: non-invasive ventilation via face mask
Study NCT02273219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds
Study NCT04124107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multiparametric MRI and 68Ga-PSMA PET/MRI
Description: All participants will undergo multiparametric MRI examination. If mpMRI is unfavorable for prostate cancer, participants will undergo 68Ga-PSMA PET/MRI examination
Study NCT04124107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Description: Participants with unfavorable mpMRI but favorable 68Ga-PSMA PET/MRI will undergo both 68Ga-PSMA PET/MRI-ultrasound-fusion targeted biopsy and transperineal ultrasound guided 12-core systematic biopsy
Study NCT03639766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Description: AbobotulinumtoxinA reconstituted in non-bacteriostatic saline solution
Study NCT03639766 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Non-bacteriostatic saline solution
Study NCT03808168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).
Study NCT04099784 — intervention group
Intervention type: OTHER
Intervention: Physical development and General Health
Description: Physical development and General health examination
Study NCT04099784 — intervention group
Intervention type: OTHER
Intervention: Developmental Red flags
Description: Developmental Red flags Questionnaires
Study NCT00005833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R115777
Description: 300mg P.O. BID.
Study NCT02321462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eziclen
Description: Eziclen solution administered orally as split-dose the day before and on the day of colonoscopy.
Study NCT02321462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fortrans®
Description: Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
Study NCT02196324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: serlopitant
Description: NK1 receptor antagonist
Study NCT02196324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02382081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-initiated shared care
Study NCT01615471 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group weight loss with companion internet
Description: Monthly in-person group sessions with an companion internet weight loss intervention
Study NCT01677091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical vibration
Description: Vibration of neck muscles during 10 minutes
Study NCT01677091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prism adaptation
Description: Prism adaptation during 10 minutes
Study NCT01677091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: conventional rehabilitation
Study NCT02635191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tailored Group
Description: All the patients who enrolled in this arm will be received endoscopy followed by biopsy for antimicrobial susceptibility testing and cytochrome P450 isoenzyme 2C19 genotype. 10 days tailored therapy will be given including one Proton Pump Inhibitor ( Rabeprazole0.4-0.5mg/kg.d,bid. or Esomeprazole0.8-1.0mg/kg.d,bid) and two antibiotics (Amoxicillin30-50mg/kg.d bid, Clarithromycin15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid ) based on the cytochrome P450 isoenzyme 2C19 genotype and the antimicrobial susceptibility.
Study NCT02635191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard group
Description: All the patients who enrolled in this arm will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) .
Study NCT01846975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Abatacept
Description: Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
Study NCT00558103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib
Description: Oral administration
Study NCT00558103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Oral administration
Study NCT00558103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Oral administration
Study NCT00558103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Oral administration
Study NCT04082988 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 18F-FDG PET-CT
Description: 18F-FDG PET-CT scan
Study NCT02112825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Blended supervised-home based walking exercise 3-4 times per week for 30-45 minutes
Study NCT01719185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine and B12
Study NCT01719185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine
Study NCT03250468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Each weekly session will focus on several psychological and behavioural techniques that include sleep restriction, relaxation strategies, cognitive therapy, stimulus control therapy, and education about proper sleep hygiene.
Study NCT00692770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Sorafenib 400 mg twice daily (BID)
Study NCT00692770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 tablets twice daily (BID)
Study NCT04248816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Subjects will receive outreach through their providers as is standard of care.
Study NCT04248816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-out
Description: Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip for them to get it done at a health system facility.
Study NCT04248816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-out + Incentive
Description: Research staff will send a letter to patients encouraging them to get a surveillance ultrasound and include an order slip plus an unconditional $20 incentive for them to get it done at a health system facility.
Study NCT01870765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow oxygen
Description: high-flow oxygen via nasal cannula
Study NCT01870765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscopy
Description: fiberoptic bronchoscopy including broncho-alveolar lavage
Study NCT02769702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Acthar 80 IU SC twice a week
Study NCT00917891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapivirine
Description: dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks
Study NCT00917891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: dosage form: vaginal gel~frequency: once daily~duration: 6 weeks
Study NCT01660828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic preconditioning (RIPC)
Description: RIPC protocol which consist of three 5-min cycles of bilateral forearm ischemia
Study NCT01076907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm water
Description: Warm water loading of sigmoid colon when spasms occur and waiting for them to subside.
Study NCT01076907 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Air will be used instead of warm water for unsedated colonoscopy.
Study NCT02199405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage of chiropractic and adjusting cervical curvature
Description: Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks
Study NCT02199405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sishi Daoyin
Description: Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
Study NCT02199405 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional massage
Description: Conventional massage , 15 minutes, three times one week for 4 weeks
Study NCT02199405 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical traction
Study NCT04492891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 2.5 mg/kg PO BID 7 days
Study NCT04492891 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Treatment
Description: Standard of Care Treatment, N= 25 Patients, 7 days
Study NCT00175890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Dosing was stratified by age. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for children one month to less than six months old and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.
Study NCT00175890 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution, which is indistinguishable from the Levetiracetam oral solution.
Study NCT03325686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D supplement
Description: D; received 50,000 IU of vitamin D supplement weekly
Study NCT03325686 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01892696 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: varying inspiratory flow waveforms
Description: inspiratory flow waveform was changed, in a randomized sequence using a computer ,to one of the following modalities: 1) constant inspiratory flow; 2) decelerating inspiratory flow Each inspiratory flow waveform was maintained for 30 min. During the last 5 min of this period the physiological signals were collected and measures were performed.
Study NCT00816101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procellera™ Antimicrobial Dressing
Description: Dressing indicated for partial and full-thickness wounds.
Study NCT00816101 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex® Border Lite
Description: Self-adherent foam dressing
Study NCT00816101 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adhesive Bandage
Description: Adhesive bandage
Study NCT03829046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weeks of treatment
Study NCT03829046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: 12 weeks of treatment
Study NCT03674736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intakes
Description: Four levels of methionine or lysine intakes will be provided by the reference protein drinks, 3 levels of methionine from rice and wheat bread and 3 levels of lysine from chickpeas and lentils
Study NCT01870765 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic bronchoscopy
Description: fiberoptic bronchoscopy including broncho-alveolar lavage